View More View Less
  • 1 Faculty of Medicine, Semmelweis University 2nd Department of Medicine Szentkirályi u. 46 H-1088 Budapest Hungary
  • | 2 Semmelweis University – Hungarian Academy of Sciences Research Group of Molecular Medicine Budapest Hungary
Restricted access

Introduction: Hormonally inactive carcinoids represent a significant proportion of all carcinoids tumours. Classical biochemical and hormonal parameters are not suitable for the diagnosis and follow-up of these tumours. However, the tumour marker chromogranin A that is characteristic for several neuroendocrine tumours and secreted by the majority of these tumours as well, may offer a better means of diagnosis and follow-up. Somatostatin receptors are expressed by hormonally inactive carcinoids and the presence of these receptors has important diagnostic and therapeutic consequences. Case report: The authors present the history of a patient with a hormonally inactive bronchial carcinoid tumour. After surgical removal of the bronchial carcinoid, liver metastases developed which were found to be somatostatin receptor positive. Somatostatin analogue treatment was introduced, followed by Yttrium-isotope labelled somatostatin analogue therapy. Serum chromogranin A was elevated before somatostatin treatment, and gradually decreased in parallel with therapy. The size of liver metastases remained unchanged during treatment. Conclusions: Chromogranin A can be efficiently applied for the clinical follow-up of hormonally inactive carcinoid tumours. Somatostatin analogues may be effective for preventing tumour progression not only in hormone-secreting but also in hormonally inactive carcinoid tumours.

  • Tóth, M., Prónai, L., Németh, A. M., Tulassay, Z.: Carcinoid neoplasms. Orv. Hetil., 2002, 143 , 1087–1092.

    Tulassay Z. , 'Carcinoid neoplasms ' (2002 ) 143 Orv. Hetil. : 1087 -1092.

  • Barakat, M. T., Meeran, K., Bloom, S. R.: Neuroendocrine tumours. Endocrine Relat. Cancer, 2004, 11 , 1–18.

    Bloom S. R. , 'Neuroendocrine tumours ' (2004 ) 11 Endocrine Relat. Cancer : 1 -18.

  • Lamberts, S. W. J., Hofland, L. J., Nobels, F. R. E.: Neuroendocrine tumor markers. Front. Neuroendocrinol., 2001, 22 , 309–339.

    Nobels F. R. E. , 'Neuroendocrine tumor markers ' (2001 ) 22 Front. Neuroendocrinol. : 309 -339.

    • Search Google Scholar
  • Lenders, J. W. M., Eisenhofer, G., Mannelli, M., Pacak, K.: Phaeochromocytoma. Lancet, 2005, 66 , 665–675.

    Pacak K. , 'Phaeochromocytoma ' (2005 ) 66 Lancet : 665 -675.

  • Kaltsas, G. A., Besser, G. M., Grossman, A. B.: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev., 2004, 25 , 458–511.

    Grossman A. B. , 'The diagnosis and medical management of advanced neuroendocrine tumors ' (2004 ) 25 Endocr. Rev. : 458 -511.

    • Search Google Scholar
  • Baudin, E., Bidart, J. M., Bachelot, A., Ducreux, M., Elias, D., Ruffie, P., Schlumberger, M.: Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol., 2001, 12 (Suppl. 2) , S79–S82.

    Schlumberger M. , 'Impact of chromogranin A measurement in the work-up of neuroendocrine tumors ' (2001 ) 12 Ann. Oncol. : S79 -S82.

    • Search Google Scholar
  • Perracchi, M., Conte, D., Gebbia, C., Penati, C., Pizzinelli, S., Arosio, M., Corbetta, S., Spada, A.: Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur. J. Endocrinol., 2003, 148 , 39–43.

    Spada A. , 'Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1 ' (2003 ) 148 Eur. J. Endocrinol. : 39 -43.

    • Search Google Scholar
  • Giovanella, L., La Rosa, S., Ceriani, L., Uccella, S., Erba, P., Garancini, S.: Chromogranin A as serum marker of neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int. J. Biol. Markers, 1999, 14 , 160–166.

    Garancini S. , 'Chromogranin A as serum marker of neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings ' (1999 ) 14 Int. J. Biol. Markers : 160 -166.

    • Search Google Scholar
  • Nobels, F. R., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H., Lindemans, J., de Herder, W. W., Krenning, E. P., Bouillon, R., Lamberts, S. W.: Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab., 1997, 82 , 2622–2628.

    Lamberts S. W. , 'Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones ' (1997 ) 82 J. Clin. Endocrinol. Metab. : 2622 -2628.

    • Search Google Scholar
  • Bajetta, E., Ferrari, L., Martinetti, A., Celio, L., Procopio, G., Artale, S., Zilembo, N., di Bartolomeo, M., Seregni, E., Bombardieri, E.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 1999, 86 , 858–865.

    Bombardieri E. , 'Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors ' (1999 ) 86 Cancer : 858 -865.

    • Search Google Scholar
  • Tomassetti, P., Migliori, M., Simoni, P., Casadei, R., Di Lasio, R., Corinaldesi, R., Gullo, L.: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol., 2001, 13 , 55–58.

    Gullo L. , 'Diagnostic value of plasma chromogranin A in neuroendocrine tumours ' (2001 ) 13 Eur. J. Gastroenterol. Hepatol. : 55 -58.

    • Search Google Scholar
  • Stridsberg, M., Öberg, K., Li, Q., Engström, U., Lundqvist, G.: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J. Endocrinol., 1995, 144 , 49–59.

    Lundqvist G. , 'Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours ' (1995 ) 144 J. Endocrinol. : 49 -59.

    • Search Google Scholar
  • Baudin, E., Gigliotti, A., Ducreux, M., Ropers, J., Comoy, E., Sabourin, J. C., Bidart, J. M., Cailleux, A. F., Bonacci, R., Ruffié, P., Schlumberger, M.: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br. J. Cancer, 1998, 78 , 1102–1107.

    Schlumberger M. , 'Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours ' (1998 ) 78 Br. J. Cancer : 1102 -1107.

    • Search Google Scholar
  • Kölby, L., Bernhardt, P., Swärd, C., Johanson, V., Ahlman, H., Forssel-Allonson, E., Stridsberg, M., Wangberg, B., Nilsson, O.: Chromogranin A as a determinant of midgut carcinoid tumour volume. Reg. Pept., 2004, 120 , 269–273.

    Nilsson O. , 'Chromogranin A as a determinant of midgut carcinoid tumour volume ' (2004 ) 120 Reg. Pept. : 269 -273.

    • Search Google Scholar
  • Sondenaa, K., Sen, J., Heinle, F., Fjetland, L., Gudlaugsson, E., Syversen, U.: Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J. Surg., 2004, 28 , 890–895.

    Syversen U. , 'Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report ' (2004 ) 28 World J. Surg. : 890 -895.

    • Search Google Scholar
  • Nobels, F. R. E., Kwekkeboom, D. J., Bouillon, R., Lamberts, S. W.: Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest., 1998, 28 , 431–440.

    Lamberts S. W. , 'Chromogranin A: its clinical value as marker of neuroendocrine tumours ' (1998 ) 28 Eur. J. Clin. Invest. : 431 -440.

    • Search Google Scholar
  • Abou-Saif, A., Gibril, F., Ojeaburu, J. V., Bashir, S., Entsuah, L. K., Asgharian, B., Jensen, R. T.: Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer, 2003, 98 , 249–261.

    Jensen R. T. , 'Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas ' (2003 ) 98 Cancer : 249 -261.

    • Search Google Scholar
  • Nehar, D., Lombard-Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J. A., Penes, M. C., Sassolas, G., Borson-Chazot, F.: Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin. Endocrinol., 2004, 80 , 644–652.

    Borson-Chazot F. , 'Interest of chromogranin A for diagnosis and follow-up of endocrine tumours ' (2004 ) 80 Clin. Endocrinol. : 644 -652.

    • Search Google Scholar
  • Öberg, K., Eriksson, B.: Endocrine tumours of the pancreas. Best Pract. Res. Clin. Gastroenterol., 2005, 19 , 753–781.

    Eriksson B. , 'Endocrine tumours of the pancreas ' (2005 ) 19 Best Pract. Res. Clin. Gastroenterol. : 753 -781.

    • Search Google Scholar
  • Bondanelli, M., Ambrosio, M. R., Zatelli, M. C., Cavazzini, L., Al Jandaly Rifa’y, L., degli Uberti, E. C.: Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy. World J. Gastroenterol., 2005, 11 , 2041–2044.

    Uberti E. C. , 'Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy ' (2005 ) 11 World J. Gastroenterol. : 2041 -2044.

    • Search Google Scholar
  • Prónai, L., Rácz, K., Tulassay, Z.: Gastroenteropancreatic neuroendocrine tumors. Orv. Hetil., 2002, 143 , 1081–1086.

    Tulassay Z. , 'Gastroenteropancreatic neuroendocrine tumors ' (2002 ) 143 Orv. Hetil. : 1081 -1086.

    • Search Google Scholar
  • Cebon, J. and Australasian Gastro-Intestinal Trials Group (AGITG) AG0000IH Investigators: Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellulary carcinoma treated with long-acting octreotide. Br. J. Cancer, 2006, 95 , 853–861.

    Cebon J. , 'Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellulary carcinoma treated with long-acting octreotide ' (2006 ) 95 Br. J. Cancer : 853 -861.

    • Search Google Scholar
  • Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Koninjenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., Krenning, E. P.: [177-Lu-DOTA O Tyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med., 2001, 28 , 1319–1325.

    Krenning E. P. , '[177-Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients ' (2001 ) 28 Eur. J. Nucl. Med. : 1319 -1325.

    • Search Google Scholar
  • Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J. P., Kam, B. L., Krenning, E. P.: Radiolabeled somatostatin analog [177-Lu-DOTA O Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol., 2005, 23 , 2754–2762.

    Krenning E. P. , 'Radiolabeled somatostatin analog [177-Lu-DOTAOTyr3]octreotate in patients with endocrine gastroenteropancreatic tumors ' (2005 ) 23 J. Clin. Oncol. : 2754 -2762.

    • Search Google Scholar
  • Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., Müller-Brand, J.: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol., 2001, 12 , 941–945.

    Müller-Brand J. , 'The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study ' (2001 ) 12 Ann. Oncol. : 941 -945.

    • Search Google Scholar

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 2 0 0
Jul 2021 1 0 0
Aug 2021 4 0 0
Sep 2021 1 0 0
Oct 2021 2 0 0
Nov 2021 0 0 0
Dec 2021 0 0 0